XPhyto Secures Exclusive Psychedelic Drug Development Agreement
The Pharma Data
NOVEMBER 9, 2020
. “Our initial focus is to develop standardized drug formulations with precise, predictable and efficient API delivery for clinical study and therapeutic use.” Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
Let's personalize your content